Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Raltegravir treatment response in an HIV-2 infected patient: a case report

23 May 2008

Abstract excerpt

Raltegravir (RAL) (MK-0518), a novel and potent inhibitor of HIV-1 integrase, has been shown to be effective in reducing viral activity in both heavily antiretroviral treatment-experienced [1] and treatment-naïve [2] HIV-1 infected patients. In HIV-1, RAL appears to have a relatively low genetic barrier to resistance [3] but cross-resistance occurs with other drugs of the class [4]. Data exist on the mutation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV/AIDS Research and Interventions
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18520356
DOI: 10.1097/qad.0b013e3282f9b165

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Raltegravir treatment response in an HIV-2 infected patient: a case reportPMID 18520356Read ↗

Antiretroviral drug-resistant HIV-2 infection--a new therapeutic dilemma.Semantic proximity Read ↗

The role of raltegravir in the treatment of HIV-2 infections: evidence from a case series.Semantic proximity Read ↗

Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc.Semantic proximity Read ↗

Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.Semantic proximity Read ↗

Dolutegravir for the treatment of HIV-2 infection.Semantic proximity Read ↗

Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.Semantic proximity Read ↗

Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients.Semantic proximity Read ↗

Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.